Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
FDA Achieves Historically Low Eight-Month Median Drug Review Time In 2017
Median review times for US agency's drug center were 10 months from 2011 to 2013, and 11 months from 2015 to 2016.
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
The latest drug development news and highlights from our FDA Performance Tracker.